幽门螺杆菌
癌症
医学
接种疫苗
疾病
免疫学
抗生素耐药性
抗菌剂
微生物学
抗生素
内科学
生物
作者
Verena Friedrich,Markus Gerhard
标识
DOI:10.1016/j.mam.2023.101183
摘要
The gram-negative bacterium Helicobacter pylori is the most common chronic bacterial infection and the main cause of gastric cancer. Due to the increasing antimicrobial resistance of H. pylori, the development of an efficacious vaccine is a valid option to protect from disease or infection and ultimately prevent gastric cancer. However, despite more than 30 years of research, no vaccine has entered the market yet. This review highlights the most relevant previous preclinical and clinical studies to allow conclusions to be drawn on which parameters need special attention in the future to develop an efficacious vaccine against H. pylori and thus prevent gastric cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI